Focused Ultrasounds As an Adeno-Associated Virus Gene Therapy-Empowering Tool in Juvenile Mice Via Intracerebroventricular Administration

Overview

Journal Hum Gene Ther

Specialties Genetics
Pharmacology

Date 2024 Nov 25

PMID 39585211

Authors

Alessandro Zappala

Heng Li

Ken Inoue

Affiliations

Soon will be listed here.

Abstract

Systemic delivery of adeno-associated virus (AAV) vectors targeting the central nervous system has the potential to solve many neurodevelopmental disorders, yet it is made difficult by the filtering effect of the blood-brain barrier and systemic complications. To overcome this limitation, we attempted to inject a Venus-expressing, oligodendrocyte-selective AAV9 viral vector in the ventricles together with lipid microbubbles and subjected them to focused ultrasound (FUS); the resulting mechanical stimulation on the brain ventricles is able to open small, temporary gaps from which vector particles can leak and spread. Our findings indicate that FUS can increase viral vector diffusion across both the anteroposterior and left-right axes without influencing cell tropism; significant effects were found with 60 and 90 s exposure time, but no effects were observed with longer intervals. Taken together, these results highlight a new strategy for the safe and effective delivery of viral vectors and offer new perspectives for the development and application of gene therapies for central nervous system diseases.

References

Ogawa K, Fuchigami Y, Hagimori M, Fumoto S, Maruyama K, Kawakami S . Ultrasound-responsive nanobubble-mediated gene transfection in the cerebroventricular region by intracerebroventricular administration in mice. Eur J Pharm Biopharm. 2019; 137:1-8. DOI: 10.1016/j.ejpb.2019.02.003. View

Felix M, Borloz E, Metwally K, Dauba A, Larrat B, Matagne V . Ultrasound-Mediated Blood-Brain Barrier Opening Improves Whole Brain Gene Delivery in Mice. Pharmaceutics. 2021; 13(8). PMC: 8399273. DOI: 10.3390/pharmaceutics13081245. View

Inoue K . Pelizaeus-Merzbacher Disease: Molecular and Cellular Pathologies and Associated Phenotypes. Adv Exp Med Biol. 2019; 1190:201-216. DOI: 10.1007/978-981-32-9636-7_13. View

Weber-Adrian D, Kofoed R, Silburt J, Noroozian Z, Shah K, Burgess A . Systemic AAV6-synapsin-GFP administration results in lower liver biodistribution, compared to AAV1&2 and AAV9, with neuronal expression following ultrasound-mediated brain delivery. Sci Rep. 2021; 11(1):1934. PMC: 7820310. DOI: 10.1038/s41598-021-81046-5. View

Castle M, Turunen H, Vandenberghe L, Wolfe J . Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. Methods Mol Biol. 2015; 1382:133-49. PMC: 4993104. DOI: 10.1007/978-1-4939-3271-9_10. View

. Developmental disabilities among children younger than 5 years in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Glob Health. 2018; 6(10):e1100-e1121. PMC: 6139259. DOI: 10.1016/S2214-109X(18)30309-7. View

Li H, Okada H, Suzuki S, Sakai K, Izumi H, Matsushima Y . Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA. JCI Insight. 2019; 4(10). PMC: 6542614. DOI: 10.1172/jci.insight.125052. View

Dasgupta A, Liu M, Ojha T, Storm G, Kiessling F, Lammers T . Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. Drug Discov Today Technol. 2016; 20:41-48. PMC: 5166975. DOI: 10.1016/j.ddtec.2016.07.007. View

Vanderver A, Prust M, Tonduti D, Mochel F, Hussey H, Helman G . Case definition and classification of leukodystrophies and leukoencephalopathies. Mol Genet Metab. 2015; 114(4):494-500. PMC: 4390457. DOI: 10.1016/j.ymgme.2015.01.006. View

10.

Hsu P, Wei K, Huang C, Wen C, Yen T, Liu C . Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound. PLoS One. 2013; 8(2):e57682. PMC: 3584045. DOI: 10.1371/journal.pone.0057682. View

11.

Belur L, Romero M, Lee J, Podetz-Pedersen K, Nan Z, Riedl M . Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I. Front Mol Neurosci. 2021; 14:618360. PMC: 8141728. DOI: 10.3389/fnmol.2021.618360. View

12.

Tomono T, Hirai Y, Okada H, Adachi K, Ishii A, Shimada T . Ultracentrifugation-free chromatography-mediated large-scale purification of recombinant adeno-associated virus serotype 1 (rAAV1). Mol Ther Methods Clin Dev. 2016; 3:15058. PMC: 4748944. DOI: 10.1038/mtm.2015.58. View

13.

Foust K, Nurre E, Montgomery C, Hernandez A, Chan C, Kaspar B . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2008; 27(1):59-65. PMC: 2895694. DOI: 10.1038/nbt.1515. View

14.

Spector R, Johanson C . The mammalian choroid plexus. Sci Am. 1989; 261(5):68-74. DOI: 10.1038/scientificamerican1189-68. View

15.

Bey K, Ciron C, Dubreil L, Deniaud J, Ledevin M, Cristini J . Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders. Gene Ther. 2017; 24(5):325-332. DOI: 10.1038/gt.2017.18. View

16.

Johnston S, Parylak S, Kim S, Mac N, Lim C, Gallina I . AAV ablates neurogenesis in the adult murine hippocampus. Elife. 2021; 10. PMC: 8331179. DOI: 10.7554/eLife.59291. View

17.

Tan J, Pham B, Zong Y, Perez C, Maris D, Hemphill A . Microbubbles and ultrasound increase intraventricular polyplex gene transfer to the brain. J Control Release. 2016; 231:86-93. PMC: 4944389. DOI: 10.1016/j.jconrel.2016.02.003. View

18.

Vykhodtseva N, McDannold N, Hynynen K . Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics. 2008; 48(4):279-96. PMC: 2569868. DOI: 10.1016/j.ultras.2008.04.004. View